Economic evaluation of monoclonal antibody in the management of colorectal cancer
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 1
Abstract
Objective: This study aims to determine the cost of colorectal cancer (CRC) management and compare the cost effectiveness of cetuximab and bevacizumab in the management of CRC. Method: This economic evaluation study from a societal perspective involves collecting resource utilization data based on the clinical pathway of colorectal cancer management. The cost calculated includes drugs, human resources, administrative, investigations as well as capital cost. Patient’s cost was also calculated based on an interview with colorectal cancer patients. Effectiveness estimates for monoclonal antibody (cetuximab and bevacizumab) treatment were modeled from study respondents based on references from other studies. Results: Cost of treating a case of colorectal cancer in stage I is RM13,623 (RM12,467-RM14,777), stage II RM19,753 (RM16,734-RM23,520), stage III RM24,972 (RM20,291-RM29,654) and stage IV RM27, 163 (RM23, 192-RM31,133). Cost of CRC management increase with the increasing stage of the disease (Kruskal Wallis, X2=106, p<0.001). Based on estimates of 2671 new cases of CRC, the incremental cost of cetuximab is RM20, 556 480 and bevacizumab is RM7,557,953 at 50% stage III and IV as compared to the conventional chemotherapy. The incremental cost per quality adjusted life years gained for cetuximab is RM38,869 and RM14,290 for bevacizumab. Although both types of monoclonal antibody are considered cost effective (based on WHO guidelines of less than three times of GDP), bevacizumab is considered more cost effective than cetuximab. Cost effectiveness was sensitive to the percentage of late stages of CRC. Conclusions: Cost of treating late stage of CRC is high and bevacizumab are more cost effective compared to cetuximab in the management of the late stage of CRC.
Authors and Affiliations
Ezat SW, Natrah MS, Aljunid S, Rizal MA, Saperi S, Ismail S, Fuad I, Azrif MA
Keywords
Related Articles
- EP ID EP549497
- DOI 10.14312/2052-4994.2013-5
- Views 67
- Downloads 0
Half-times of irradiation recovery in accelerated partialbreast irradiation: Incomplete recovery as a potentially dangerous enhancer of radiation damage
Purpose: To compare clinical results from accelerated partial breast irradiation with predictions from different half-times of recovery of radiation damage. Method: Three published results of excessive late complications...
Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay
In order to analyze detailed anthropometric characterisation for risk of breast cancer (BC) in premenopausal Uruguayan women, a case-control study was carried out at the Pereira Rossell Women’s Hospital, Montevideo, wher...
Gastrointestinal stromal tumour: From the clinic to the molecules
GastroIntestional stromal tumours (GISTs), the most frequent sarcoma in the gastro-intestinal (GI) tract, are highly resistant to conventional chemotherapy and radiotherapy. These tumours have activating mutations in two...
Prognostic serum biomarkers for colorectal cancer – Review
Background: Colorectal cancer (CRC) is one of the most common malignancies in developed countries. Research for diagnostic and prognostic biomarkers is increasing. There are more than 750,000 papers indexed in PubMed dir...
Changing clinical picture of endemic Burkitt’s lymphoma with improved diagnostic technology: A systematic review
We evaluated the changes in anatomical locations of endemic Burkitt’s lymphoma (eBL) by systematic review. We compared the reports before ultrasound became a routine investigation in Burkitt’s lymphoma (BL) diagnosis wit...